ArticleRMD open2021
Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers.
Article in RMD open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Arrhythmias and Conduction Disturbances in Patients with Systemic Sclerosis-A Systematic Literature Review.International journal of molecular sciences · 2022Pooled it
- Society for cardiovascular magnetic resonance expert consensus statement on quantitative myocardial perfusion cardiovascular magnetic resonance imaging.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic ResonanceGuideline
- Primary heart involvement assessed by cardiac magnetic resonance is associated with capillaroscopy abnormalities in systemic sclerosis.Advances in rheumatology (London, England) · 2026Article
- Individualized care or standardized protocol: should all patients with systemic sclerosis receive cardiac MRI?Rheumatology (Oxford, England) · 2026Article
- Cardio-rheumatology: integrated care and the opportunities for personalized medicine.Therapeutic advances in musculoskeletal disease · 2025Review
- Novel Insights into Causal Effects of Serum Lipids and Apolipoproteins on Cardiovascular Morpho-Functional Phenotypes.Cardiovascular toxicology · 2024Article
- Cardiovascular Computed Tomography and Magnetic Resonance Imaging Guideline of the Brazilian Society of Cardiology and the Brazilian College of Radiology - 2024.Arquivos brasileiros de cardiologia · 2024Article
- Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases.Nature reviews. Rheumatology · 2024Review
- Biomarkers in the evaluation of cardiac involvement in systemic sclerosis.Rheumatology and immunology research · 2024Article
- The role of comprehensive stress cardiac MRI in autoimmune rheumatic disease: A review.International journal of cardiology. Heart & vasculature · 2024Review
- Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis.Journal of clinical medicine · 2023Article
- Serum markers in systemic sclerosis with cardiac involvement.Clinical rheumatology · 2023Review
- Cardiac involved and autopsy in two patients with systemic sclerosis: Two cases report.Heliyon · 2023Article
- Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change.ACR open rheumatology · 2023Article
- The Involvement of Smooth Muscle, Striated Muscle, and the Myocardium in Scleroderma: A Review.International journal of molecular sciences · 2022Review
- Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the prognostic value of subclinical cardiovascular (CV) imaging measures and serum cardiac biomarkers in systemic sclerosis (SSc) for the development of CV outcomes of primary heart involvement (pHI).
methodsPatients with SSc with no clinical SSc-pHI and no history of heart disease underwent cardiovascular magnetic resonance (CMR) imaging, and measurement of serum high-sensitivity-troponin I (hs-TnI) and N-terminal-pro-brain natriuretic peptide (NT-proBNP). Follow-up clinical and CV outcome data were recorded. CV outcomes were defined as myocarditis, arrhythmia and/or echocardiographic functional impairment including systolic dysfunction and/or diastolic dysfunction.
resultsSeventy-four patients with a median (IQR) age of 57 (49, 63) years, 32% diffuse cutaneous SSc, 39% interstitial lung disease, 30% Scl70+ were followed up for median (IQR) 22 (15, 54) months. Ten patients developed CV outcomes, comprising one patient with myocarditis and systolic dysfunction and nine arrhythmias: three non-sustained ventricular tachycardia and six supraventricular arrhythmias. The probability of CV outcomes was considerably higher in those with NT-proBNP >125 pg/mL versus normal NT-proBNP (X
conclusionThese data indicate standard serum cardiac biomarkers (notably NT-proBNP) and CMR indices of myocardial fibrosis associate with adverse CV outcomes in SSc. This forms the basis to develop a prognostic model in larger, longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.